Media Coverage

Home / About Us / News Center / Media Coverage / Rare Community Profiles: Inozyme’s Catherine Nester Discusses Newborn Screening and the GACI Diagnostic Delay

Rare Community Profiles: Inozyme’s Catherine Nester Discusses Newborn Screening and the GACI Diagnostic Delay

Patient Worthy

September 27, 2023

Catherine Nester spoke with Patient Worthy about the importance of newborn screening, the challenges of diagnostic delays, and how Inozyme is working to transform the treatment landscape for ENPP1 Deficiency and ABCC6 Deficiency, also known as Generalized Arterial Calcification of Infancy (GACI) types 1 and 2, respectively.

View on Patient Worthy Website

BeginNGS, collaborations, GACI, genomic newborn screening, Inozyme Pharma, rare disease, rare disease diagnosis, Spotlight